+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Enhancer of zeste homolog 2 protein inhibitors - Pipeline Insight, 2022

  • ID: 5310605
  • Clinical Trials
  • January 2022
  • Region: Global
  • 60 Pages
  • DelveInsight

FEATURED COMPANIES

  • Daiichi Sankyo
  • Epizyme, Inc.
  • Inventiva Pharma
  • Ionis Pharmaceuticals
  • Pfizer
This “Enhancer of zeste homolog 2 protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Enhancer of zeste homolog 2 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Enhancer of zeste homolog 2 protein inhibitors Understanding

Enhancer of zeste homolog 2 protein inhibitors: Overview


Enhancer of zeste homolog 2 is a component of the Polycomb repressive complex 2 that mediates chromatin-based gene silencing through trimethylation of lysine 27 on histone H3. This complex plays vital roles in the regulation of development-specific gene expression.

Function - Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme encoded by EZH2 gene, that participates in histone methylation and, ultimately, transcriptional repression. EZH2 catalyzes the addition of methyl groups to histone H3 at lysine 27, by using the cofactor S-adenosyl-L-methionine. Mutation or over-expression of EZH2 has been linked to many forms of cancer. EZH2 inhibits genes responsible for suppressing tumor development, and blocking EZH2 activity may slow tumor growth. EZH2 has been targeted for inhibition because it is up regulated in multiple cancers.

Enhancer of zeste homolog 2 protein inhibitors - EZH2 is upregulated in various cancers with high levels associated with metastatic cancer and poor prognosis. Dysregulation of the histone methyltransferase EZH2 plays a critical role in the development of a variety of malignancies including B-cell lymphomas.

Enhancer of zeste homolog 2 protein inhibitors Emerging Drugs Chapters


This segment of the Enhancer of zeste homolog 2 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Enhancer of zeste homolog 2 protein inhibitors Emerging Drugs

Tazemetostat: Epizyme, Inc.

Tazemetostat is a potent, selective, and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activity. EZH2, a methyltransferase plays a role in epithelioid sarcoma pathogenesis. The drug is currently being evaluated in Phase III stage of dvelopemnt for the treatment of patients with Synovial cancer and various other solid tumors.

.

CPI-1205: Constellation Pharmaceuticals

CPI-1205 is a potent, selective EZH2 inhibitor that reduces global histone H3K27 trimethylation in a reversible way. The drug is currently being evaluated in Phase I/II stage of development in combination with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer.

Enhancer of zeste homolog 2 protein inhibitors: Therapeutic Assessment


This segment of the report provides insights about the different Enhancer of zeste homolog 2 protein inhibitors drugs segregated based on following parameters that define the scope of the report.

Major Players working on Enhancer of zeste homolog 2 protein inhibitors


There are approx. 10+ key companies which are developing the Enhancer of zeste homolog 2 protein inhibitors. The companies which have their Enhancer of zeste homolog 2 protein inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Epizyme Inc.

Phases


This report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Enhancer of zeste homolog 2 protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Enhancer of zeste homolog 2 protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Enhancer of zeste homolog 2 protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Enhancer of zeste homolog 2 protein inhibitors drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Enhancer of zeste homolog 2 protein inhibitors R&D. The therapies under development are focused on novel approaches for Enhancer of zeste homolog 2 protein inhibitors.

Enhancer of zeste homolog 2 protein inhibitors Report Insights

  • Enhancer of zeste homolog 2 protein inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Enhancer of zeste homolog 2 protein inhibitors Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions


Current Scenario and Emerging Therapies:

  • How many companies are developing Enhancer of zeste homolog 2 protein inhibitors drugs?
  • How many Enhancer of zeste homolog 2 protein inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Enhancer of zeste homolog 2 protein inhibitors?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Enhancer of zeste homolog 2 protein inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Enhancer of zeste homolog 2 protein inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Daiichi Sankyo
  • Epizyme, Inc.
  • Inventiva Pharma
  • Ionis Pharmaceuticals
  • Pfizer

IntroductionExecutive Summary
Enhancer of zeste homolog 2 protein inhibitors: Overview
  • Structure
  • Mechanism of Action

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Enhancer of zeste homolog 2 protein inhibitors - Analytical Perspective
In-depth Commercial Assessment
  • Enhancer of zeste homolog 2 protein inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Enhancer of zeste homolog 2 protein inhibitors Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)
  • Comparative Analysis

Tazemetostat: Epizyme, Inc.
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

CPI-1205: Constellation Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

PF 06821497: Pfizer
  • Product Description
  • Research and Development
  • Product Development Activities

Pre-clinical and Discovery Stage Products
  • Comparative Analysis

OR S1: Daiichi Sankyo
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Enhancer of zeste homolog 2 protein inhibitors Key CompaniesEnhancer of zeste homolog 2 protein inhibitors Key ProductsEnhancer of zeste homolog 2 protein inhibitors- Unmet NeedsEnhancer of zeste homolog 2 protein inhibitors- Market Drivers and BarriersEnhancer of zeste homolog 2 protein inhibitors- Future Perspectives and ConclusionEnhancer of zeste homolog 2 protein inhibitors Analyst ViewsEnhancer of zeste homolog 2 protein inhibitors Key CompaniesAppendix
List of Tables
Table 1 Total Products for Enhancer of zeste homolog 2 protein inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Enhancer of zeste homolog 2 protein inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Constellation Pharmaceuticals
  • Epizyme, Inc.
  • Daiichi Sankyo
  • Inventiva Pharma
  • Pfizer
  • Ionis Pharmaceuticals
  • Jiangsu Hengrui Medicine Co.
Note: Product cover images may vary from those shown